tiprankstipranks
Advertisement

FSZ - ETF AI Analysis

Compare

Top Page

FSZ

First Trust Switzerland AlphaDEX Fund (FSZ)

Rating:63Neutral
Price Target:
FSZ, the First Trust Switzerland AlphaDEX Fund, has a solid but not outstanding rating, reflecting a mix of strong Swiss companies and a few more challenged names. High-quality holdings like SFS Group and Galderma, which show robust financial performance and generally positive price trends, help support the fund’s overall quality, while stocks such as Barry Callebaut, with high debt and cash flow pressures, and names facing high valuations or bearish price trends, weigh on the rating. The main risk is that several holdings show valuation concerns or weaker technical trends, which could increase volatility if market conditions worsen.
Positive Factors
Recent Performance Momentum
The ETF has shown positive performance so far this year, with especially strong gains in the most recent month.
Strong Top Contributors
Several of the largest holdings, such as SFS Group, Sandoz, Swisscom, VAT Group, and others, have delivered strong gains that support the fund’s overall results.
Focused Exposure to Switzerland
The fund is mainly invested in Swiss companies, giving investors targeted access to that market with some additional diversification from a small U.S. allocation.
Negative Factors
High Expense Ratio
The ETF charges a relatively high fee, which can eat into long-term returns compared with lower-cost funds.
Country Concentration Risk
With most of its assets in Switzerland, the fund is heavily exposed to economic and market conditions in a single country.
Mixed Performance Among Top Holdings
Several major positions, including Galderma Group, Holcim, Bucher Industries, and Galenica, have shown weak or negative performance, which can drag on the fund’s overall results.

FSZ vs. SPDR S&P 500 ETF (SPY)

FSZ Summary

FSZ, the First Trust Switzerland AlphaDEX Fund, is an ETF that follows the NASDAQ AlphaDEX Switzerland Index, focusing mainly on Swiss stocks across the total market. It holds a mix of companies in health care, finance, and general industries, including well-known names like Holcim and Swisscom. Investors might consider FSZ to gain diversified exposure to Switzerland, a country known for stable, high-quality companies, with the potential for both growth and defensive characteristics. A key risk is that the fund is concentrated in one country, so its value can go up or down based on the Swiss market and economy.
How much will it cost me?The expense ratio for the First Trust Switzerland AlphaDEX Fund (FSZ) is 0.8%, which means you’ll pay $8 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, using a rules-based strategy to select stocks with growth and value potential. Actively managed funds typically have higher costs due to the additional research and management involved.
What would affect this ETF?The FSZ ETF, which focuses on Swiss equities, could benefit from Switzerland's strong reputation for economic stability and innovation, particularly in sectors like healthcare and finance. Positive trends such as advancements in pharmaceuticals or growth in financial services could drive the ETF's performance. However, potential risks include economic slowdowns in Europe, regulatory changes affecting key sectors, or global market volatility, which could negatively impact the ETF's holdings and overall returns.

FSZ Top 10 Holdings

FSZ is a pure play on Switzerland, and its story right now is one of selective winners trying to pull along some tired names. Industrial tech player VAT Group has been a key engine, with rising momentum earlier this year, while steady climbers like SFS Group and telecom giant Swisscom help keep the ride relatively smooth. On the flip side, consumer-facing Barry Callebaut and machinery maker Bucher Industries have been lagging, acting like a brake on returns. Overall, the fund is diversified across Swiss health care, industrials, and consumer names rather than dominated by one sector or mega-cap giant.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
SFS Group AG4.90%$1.91MCHF4.94B16.28%
72
Outperform
Sandoz Group Ltd4.74%$1.85MCHF29.07B58.24%
59
Neutral
Galderma Group AG4.34%$1.70MCHF39.58B54.67%
70
Outperform
VAT Group AG4.22%$1.65MCHF19.62B77.83%
73
Outperform
Holcim3.92%$1.53MCHF38.94B-20.16%
73
Outperform
Swisscom AG3.73%$1.46MCHF33.75B17.97%
67
Neutral
Barry Callebaut AG3.58%$1.40MCHF6.18B30.52%
54
Neutral
Galenica AG3.56%$1.39MCHF4.22B-0.93%
70
Outperform
Avolta AG3.50%$1.37MCHF6.53B18.71%
66
Neutral
Bucher Industries AG3.48%$1.36MCHF3.16B-19.92%
65
Neutral

FSZ Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
81.38
Positive
100DMA
81.69
Positive
200DMA
79.54
Positive
Market Momentum
MACD
0.03
Positive
RSI
54.11
Neutral
STOCH
69.14
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FSZ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 81.51, equal to the 50-day MA of 81.38, and equal to the 200-day MA of 79.54, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 54.11 is Neutral, neither overbought nor oversold. The STOCH value of 69.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSZ.

FSZ Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$40.95M0.80%
63
Neutral
$1.89B0.50%
71
Outperform
$97.19M0.80%
68
Neutral
$80.58M0.09%
70
Neutral
$72.01M0.45%
60
Neutral
$70.45M0.09%
63
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FSZ
First Trust Switzerland AlphaDEX Fund
82.17
8.54
11.60%
EWL
iShares MSCI Switzerland ETF
FGM
First Trust Germany AlphaDEX Fund
FLSW
Franklin FTSE Switzerland ETF
DBEZ
Xtrackers MSCI Eurozone Hedged Equity ETF
FLEU
Franklin FTSE Eurozone ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement